Overview

Update
Total Equity Funding
$58.17M in 7 Rounds from 9 Investors
Most Recent Funding
$3.08M Venture on May 7, 2015
Headquarters:
Seattle, WA
Description:
Theraclone Sciences is a biotech company developing novel therapeutic antibodies for the treatment of infectious diseases and inflammation.
Founders:
Categories:
Therapeutics, Health Care, Biotechnology, Medical
Website:
http://www.theraclone-sciences.com
Social:

Company Details

Update

Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Funding Rounds (8) - $64.17M

Update
DateAmount / RoundValuationLead InvestorInvestors
May, 2015$3.08M / Venture0
Mar, 2013$8M / Series B8
Mar, 2013$6M / Debt Financing2
Nov, 2011$11.58M / Series B0
Mar, 2010$1.5M / Series B6
Mar, 2007$29M / Series B6
Mar, 2006$4.6M / Series A3
Dec, 2004$408k / Series A0

Current Team (5)

Update

Board Members and Advisors (4)

Update

Offices/Locations (1)

Update
  • Office

    Seattle Life Sciences Building

    1124 Columbia Street, Suite 300

    Seattle, WA 98104

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos